Welcome to our dedicated page for Centessa Pharmaceuticals plc American Depositary Shares news (Ticker: CNTA), a resource for investors and traders seeking the latest updates and insights on Centessa Pharmaceuticals plc American Depositary Shares stock.
Centessa Pharmaceuticals plc (NASDAQ: CNTA) is a next-generation biopharmaceutical company based in Cambridge, Massachusetts, dedicated to transforming the traditional drug development model. By leveraging an asset-centric R&D approach at scale, Centessa is advancing a robust pipeline of highly validated programs led by industry-leading teams. Each program is managed by a Centessa subsidiary and supported by a centralized infrastructure and executive management team.
The company’s clinical-stage assets include:
- SerpinPC - A novel treatment for Hemophilia A and B, currently in Phase 2b trials. SerpinPC is a subcutaneously administered inhibitor of APC, aiming to provide effective treatment irrespective of severity or inhibitor status.
- LB101 - A cutting-edge PD-L1xCD47 LockBody, targeting solid tumors. LB101 is currently in a Phase 1/2a clinical trial, designed to selectively drive potent effector functions to the tumor micro-environment while minimizing systemic toxicity.
- ORX750 - An orally administered, highly selective orexin receptor 2 (OX2R) agonist for Narcolepsy Type 1 (NT1) and other sleep disorders, currently in its Phase 1 clinical study.
- MGX292 - Targeting Pulmonary Arterial Hypertension (PAH).
- Undisclosed programs targeting solid tumors.
Recent Achievements include:
- Phase 2b study PRESent-3 of SerpinPC showing promising preliminary results.
- FDA Fast Track designation for SerpinPC in treating Hemophilia B.
- Progress in LB101's Phase 1/2a clinical trial.
- Launch of the Phase 1 study for ORX750, with initial proof-of-concept data in sleep-deprived healthy volunteers expected later this year.
Centessa’s innovative approach and comprehensive pipeline aim to deliver transformational medicines to patients, setting a new standard of care. For more information, visit their official website at http://www.centessa.com/.
Transgene (Euronext Paris: TNG) has proposed Carol Stuckley as an independent Director, enhancing its corporate governance with an emphasis on director independence and gender diversity. Stuckley, a seasoned financial executive with over 35 years of experience, is currently a Board Director at Centessa Pharmaceuticals and has held key roles at Ipsen and Galderma North America. This nomination comes after the resignation of Laurence Espinasse. Shareholders will vote on Stuckley's appointment at the General Meeting scheduled for May 5, 2023. If approved, Transgene's Board will consist of 10 members, 6 of whom will be independent, contributing diverse skills aligned with its strategic needs.
HDAX Therapeutics has appointed Dr. Roman Fleck as Executive Chairman and Dr. Neal I. Muni as an independent Board member, enhancing the leadership team's strategic capabilities. Dr. Fleck brings extensive experience from roles at Janpix, Inc. and Medicxi Ventures, while Dr. Muni has over 20 years in the biopharmaceutical sector and is currently the COO of Comera Life Sciences (NASDAQ:CMRA). Both are expected to advance HDAX's development of first-in-class therapies targeting neurological and cardiac diseases linked to microtubule dysfunction, which have significant unmet needs. Their appointments come at a critical juncture for HDAX, as the company aims to leverage its innovative platform technology for potential breakthroughs in treatment.
Centessa Pharmaceuticals (Nasdaq: CNTA) reported significant advancements in 2022, including the initiation of a registration program for SerpinPC to treat hemophilia B and the first subject dosed in a Phase 1/2a trial for LB101, a PD-L1xCD47 bispecific antibody for solid tumors. The company also introduced ORX750, an orexin receptor-2 agonist for narcolepsy. With a strong cash position of $393.6 million, Centessa expects to fund its operations into 2026. R&D expenses decreased, leading to a reduced net loss of $43.2 million in Q4 2022. The ongoing clinical programs and significant cash runway position Centessa for future growth.
Centessa Pharmaceuticals plc (Nasdaq: CNTA) has announced its participation in two upcoming investor conferences:
- Guggenheim Genomic Medicines and Rare Disease Days
Date: April 3, 2023, Location: New York, NY, Fireside Chat: 9:35 AM ET - Jefferies & Venrock Boston Biotech Summit
Date: April 12, 2023
Presentation materials along with live webcasts and archived recordings will be accessible through the investor relations section of Centessa's website. Established to innovate in patient care, Centessa focuses on developing medicines across various stages targeting significant health issues.
Clarivate Plc (NYSE: CLVT) announced the appointment of Gordon Samson as President of its Intellectual Property (IP) market segment, effective April 1, 2023. Previously serving as Chief Product Officer, Samson aims to drive growth in the IP sector. The company also nominated Dr. Saurabh Saha for election to the Board at the Annual General Meeting on May 4, 2023. Dr. Saha, currently CEO of Centessa Pharmaceuticals (NASDAQ: CNTA), brings extensive experience in pharmaceuticals and biotech. This strategic move is to enhance leadership as Clarivate executes its growth strategy in Life Sciences & Healthcare.
Clarivate Plc (NYSE: CLVT) has announced the appointment of Gordon Samson as President of its Intellectual Property market segment, effective April 1, 2023. This new role aims to enhance growth within the IP sector. Additionally, Dr. Saurabh Saha has been nominated for election as an Independent Director at the upcoming 2023 Annual General Meeting on May 4, 2023. Dr. Saha, currently CEO of Centessa Pharmaceuticals (NASDAQ: CNTA), brings extensive experience in the pharmaceutical and biotech fields. Clarivate's CEO, Jonathan Gear, expressed confidence in Samson's ability to drive innovation and growth.
FAQ
What is the current stock price of Centessa Pharmaceuticals plc American Depositary Shares (CNTA)?
What is the market cap of Centessa Pharmaceuticals plc American Depositary Shares (CNTA)?
What does Centessa Pharmaceuticals specialize in?
Where is Centessa Pharmaceuticals headquartered?
What is SerpinPC?
What stage is LB101 in?
What is the focus of ORX750?
Has SerpinPC received any special designations?
What kind of development model does Centessa Pharmaceuticals use?
What other programs are in Centessa's pipeline?
What recent achievements has Centessa Pharmaceuticals made?
How can I find more information about Centessa Pharmaceuticals?
